Company Information

Skye Bioscience (Nasdaq: SKYE) is a biopharmaceutical company focused on unlocking new therapeutic pathways to improve metabolic health. Backed by specialist life science investors, Skye is leveraging biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation. Skye plans to launch its CBeyond^TM Phase 2 clinical trial in obesity in Q3 2024 for Nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors. This study will compare Nimacimab to placebo and in separate treatment arms, Wegovy® + Nimacimab compared to Wegovy® + placebo. Skye expects interim and topline data from its Phase 2 study in 2025.